European Journal of Cancer
Volume 42, Issue 5 , Pages 589-597 , March 2006

Malignant ascites: Systematic review and guideline for treatment

  • Gerhild Becker

      Affiliations

    • Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Str. 55, D-79106 Freiburg, Germany
    • Corresponding Author InformationCorresponding author: Tel.: +49 7612703213; fax: +49 7612703291.
    • ,
  • Daniel Galandi

      Affiliations

    • Department of Internal Medicine, HELIOS Hospital, Jostalstrasse 12, D-79822 Titisee-Neustadt, Germany
    • German Cochrane Centre, University Hospital of Freiburg, Department for Medical Statistics, Stefan-Meier-Str. 26, D-79104 Freiburg, Germany
    • ,
  • Hubert E. Blum

      Affiliations

    • Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Str. 55, D-79106 Freiburg, Germany

Received 22 October 2005 ,Revised 5 November 2005 ,Accepted 8 November 2005.

References 

  1. Taber CW. Taber’s cyclopedic medical dictionary. Philadelphia (PA): FA Davies Co.; 1965;A-92
  2. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330:337–342
  3. Ringenberg QS, Doll DC, Loy TS, et al. Malignant ascites of unknown origin. Cancer. 1989;64:753–755
  4. Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol. 2003;15:59–72
  5. Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res. 1987;42:126–132
  6. Olopade OI, Ultmann JE. Malignant effusions. CA Cancer J Clin. 1991;41(3):166–179
  7. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999–1011
  8. Lee CW, Bociek G, Faught W. A survey of practices in management of malignant ascites. J Pain Symptom Manage. 1998;16:96–101
  9. Published February 2002, last updated May 2004. Available from: <ttp://www.sign.ac.uk/guidelines/fulltext/50/index.html> [accessed 22.10.2005].
  10. Gotlieb WH, Feldman B, Feldman-Moran O, et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol. 1998;71:381–385
  11. Appelqvist P, Silvo J, Salmela L, et al. On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed?. J Surg Oncol. 1982;20:238–242
  12. Parsons SL, Watson SA, Steele RJC. Malignant ascites. Br J Surg. 1996;83:6–14
  13. Fischer DS. Abdominal paracentesis of malignant ascites. Arch Intern Med. 1979;139(2):235
  14. Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646–1654
  15. Kao HW, Rakov NE, Savage E, et al. The effect of large volume paracentesis on plasma volume – a cause of hypovolemia?. Hepatology. 1985;5:403–407
  16. Kellerman PS, Linas SL. Large volume paracentesis in treatment of ascites. Ann Intern Med. 1990;112:889–891
  17. Reynolds TB. Renaissance of paracentesis in the treatment of ascites. Adv Intern Med. 1990;112:365–374
  18. Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med. 2002;16:213–218
  19. McNamara P. Paracentesis – an effective method of symptom control in the palliative care setting?. Palliat Med. 2000;14:62–64
  20. Pockros PJ, Esrason KT, Nguyen C, et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology. 1992;103:1302–1306
  21. Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. Br J Surg. 1982;69:441–442
  22. LeVeen HH, Cristoudias G, Ip M, et al. Peritoneovenous shunting for ascites. Ann Surg. 1974;180:580–590
  23. Lund RH, Newkirk JB. Peritoneovenous shunting system for surgical management of ascites. Contemp Surg. 1979;14:31–45
  24. Fulenwider JT, Galambos JD, Smith RB, et al. Denver peritoneovenous shunts for intractable ascites of cirrhosis. A randomized prospective trial. Arch Surg. 1986;121:351–355
  25. Souter RG, Wells C, Tarin D, et al. Surgical and pathologic complications associated with peritoneovenous shunts in management of malignant ascites. Cancer. 1985;55:1973–1978
  26. Tarin D, Price JE, Kettlewell MG, et al. Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts. Br Med J (Clin Res Ed). 1984;288:749–751
  27. Gough IR. Control of malignant ascites by peritoneovenous shunting. Cancer. 1984;54:2226–2230
  28. Souter RG, Tarin D, Kettlewell MG. Peritoneovenous shunts in the management of malignant ascites. Br J Surg. 1983;70:478–481
  29. Wickremesekera SK, Stubbs RS. Peritoneovenous shunting for malignant ascites. NZ Med J. 1997;110:33–35
  30. Stuart GCE, Nation JG, Snider DD, et al. Intraperitoneal interferon in the management malignant ascites. Cancer. 1993;71:2027–2030
  31. Räth U, Kaufmann M, Schmid H, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer. 1991;27:121–137
  32. Mahler F, Rapin CH, Macgee W. Corynebacterium parvum as palliative treatment in malignant ascites. J Palliat Care. 1988;4:58–62
  33. Katano M, Torisu M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumour cell destruction. Surgery. 1983;93:365–373
  34. Torisu M, Katano M, Kimura Y, et al. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery. 1983;93:357–364
  35. Chen BM, Chan LY, Wang SM, et al. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats. Int J Cancer. 1997;73:392–402
  36. Hird V, Thomas H, Stewart JS, et al. Malignant ascites: review of the literature, and an update on monoclonal antibody-targeted therapy. Eur J Obstet Gynecol Reprod Biol. 1989;32:37–45
  37. Ariel IM, Oropeza R, Pack GT. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer: results in 267 patients. Cancer. 1966;8:1096–1102
  38. Jackson GL, Blosser NM. Intracavitary chromic phosphate (32P) colloidal suspension therapy. Cancer. 1981;48:2596–2598
  39. Twycross R, Wilcock A, Thorp S. Palliative care formulary. Oxford: Radcliffe Medical Press; 1998;
  40. Cairns W, Malone R. Octreotid as an agent for the relief of malignant ascites in palliative care patients. Palliat Med. 1999;13:429–430
  41. Sherer DM, Eliakim R, Abulafia O. The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Ostet Invest. 2000;50:217–224
  42. Xu L, Yoneda J, Herrera C, et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptortyrosine kinases. Int J Oncol. 2000;16:445–454
  43. Zucker S, Lysik RM, Zarrabi MH, et al. M (r) 92.000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993;53:140–146
  44. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res. 1998;4:1899–1902
  45. D’Errico A, Garbisa S, Liotta L, et al. Augmentation of type IV collagenase, laminin receptor and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol. 1991;4:239–246
  46. Hewitt RE, Leach ICH, Powe DG, et al. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer. 1991;49:666–672
  47. Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6:373–378
  48. Reich R, Thompson EW, Iwamoto Y, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cell. Cancer Res. 1988;48:3307–3312
  49. DeClerck YA, Perez N, Shimada H, et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992;52:701–708
  50. Davies B, Miles D, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993;53:2087–2091
  51. Wang X, Fu X, Brown PD, et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic mode in nude mice. Cancer Res. 1994;54:4726–4728
  52. Watson SA, Morris TM, Parsons SL, et al. Therapeutic effect of the matrix metalloproteinase inhibitor Batimastat in human colorectal cancer ascites model. Br J Cancer. 1996;74:1354–1358
  53. Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 1995;55:3629–3633
  54. Chirivi RG, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994;58:460–464
  55. Macaulay VM, O‘Byrne KJ, Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res. 1999;5:513–520
  56. Parsons SL, Watson SA, Steele RJC. Phase I/II trial of batimastat, a matrix Metalloproteinase inhibitor, in patients with malignant ascites. Eur J Oncol. 1997;23:526–531
  57. Ross GJ, Kesseler HB, Clair MR, et al. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. Am J Roentgenol. 1989;153:1309–1311
  58. Razis DV, Athanasiou A, Dadiotis L. Diuretics in malignant effusions and edemas of generalized cancer. J Med. 1976;7:449–461
  59. Gough IR, Balderson GA. Malignant ascites: a comparison of peritoneovenous shunting and nonoperative management. Cancer. 1993;71:2377–2382
  60. Sharma S, Walsh D. Management of symptomatic malignant ascites with diuretics: two case reports and a review of literature. J Pain Symptom Manage. 1995;3:237–242
  61. Straus AK, Roseman DL, Shapiro TM. Peritoneovenous shunting in the management of malignant ascites. Arch Surg. 1979;114:489–491
  62. Kudsk K, Fabian TC, Minton JP. Le Veen shunts in patients with intractable ascites. J Surg Oncol. 1980;13:61–66
  63. Lokich J, Reinhold R, Silverman M, et al. Complications of peritoneovenous shunt for malignant ascites. Cancer Treat Rep. 1980;64:305–309
  64. Raaf JH, Stroehlein JR. Palliation of malignant ascites by the Le Veen peritoneovenous shunt. Cancer. 1980;45:1019–1024
  65. Cheung DK, Raaf JH. Selection of patients with malignant ascites for a peritoneovenous shunt. Cancer. 1982;50:1204–1209
  66. Gough IR. Peritoneovenous shunts for malignant ascites. Aust NZ J Surg. 1982;52:47–49
  67. Qazi R, Savlov ED. Peritoneovenous shunt for palliation in malignant ascites. Cancer. 1982;49:600–602
  68. Timon C, Leahy A, Daly P, et al. Peritoneovenous shunts for malignant ascites. Ir Med J. 1987;80:179–180
  69. Millard FC, Powis SJ. Management of intractable malignant ascites using the Denver peritoneovenous shunt. J R Coll Surg Edinb. 1988;33:138–139
  70. Li MK, Shiu W, Li AK. The use of double valve denver peritoneal venous shunt for malignant ascites. Ann Acad Med Singapore. 1988;17:129–131
  71. Smith DA, Weaver DW, Bouwman DL. Peritoneous shunt (PVS) for malignant ascites: an analysis of outcome. Am J Surg. 1989;55:445–449
  72. Edney JA, Hill A, Armstrong D. Peritoneovenous shunts palliate malignant ascites. Am J Surg. 1989;158:598–601
  73. Schumacher DL, Saclarides TJ, Staren ED. Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol. 1994;1:378–381
  74. Faught W, Kirkpatrick JR, Krepart GV, et al. peritoneovenous shunt for palliation of gynecologic malignant ascites. J Am Coll Surg. 1995;180:472–474
  75. Tueche SG, Pector JC. Peritoneovenous shunt in malignant ascites. Hepatogastroenterology. 2000;47:1322–1324
  76. Bieligk SC, Calvo BF, Coit DG. Peritoneovenous shunting for nongynecologic malignant ascites. Cancer. 2001;91:1247–1255
  77. Zanon C, Grosso M, Apra F, et al. Palliative treatment of malignant refractory ascites by positioning of Denver peritoneovenous shunt. Tumouri. 2002;88:123–127
  78. Clara R, Righi D, Bortolini M, et al. Role of different techniques for the placement of Denver peritoneovenous shunt (PVS) in malignant ascites. Surg Laparosc Endosc Percutan Tech. 2004;14:222–225

PII: S0959-8049(05)01077-4

doi: 10.1016/j.ejca.2005.11.018

European Journal of Cancer
Volume 42, Issue 5 , Pages 589-597 , March 2006

Article Tools